Ovarian, breast, and metabolic changes induced by androgen treatment in transgender men

In this review of the literature, the current knowledge of ovarian, breast, and metabolic changes observed following gender-affirming hormone therapy in transgender men is discussed.

Go to the profile of Fertility and Sterility
Fertility and Sterility
Editorial Office, American Society for Reproductive Medicine
Published
Like Comment
Related Content

VOLUME 116, ISSUE 4, P936-942

Authors:

Paul Pirtea, M.D., Jean Marc Ayoubi, M.D., Ph.D., Stephanie Desmedt, M.D., Ph.D., Guy T’Sjoen, M.D., Ph.D.

Abstract:

Gender-affirming hormone therapy (GAHT) is often provided to transgender people. In this review of the literature, the current knowledge of ovarian, breast, and metabolic changes (body composition, insulin resistance, bone density, cardiovascular risk factors such as lipids, blood pressure, and hematocrit) observed following GAHT in adult transgender men is discussed.
Read the full text here. 
Go to the profile of Fertility and Sterility

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders.